文献速递糖尿病

替尔泊肽作为日本2型糖尿病患者单一口服降糖药附加治疗的安全性与疗效(SURPASS J-combo):一项多中心、随机、开放标签、平行组、3期试验

Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial.
PubMed 文献 · Lancet Diabetes Endocrinol · 2022-07-30

这项在日本34个中心进行的3期随机开放标签平行组试验,纳入443例单药口服降糖药控制不佳的2型糖尿病患者,随机接受替尔泊肽5、10或15 mg每周皮下注射52周。主要终点安全性显示多数患者发生治疗中出现的不良事件,15 mg组不良事件发生率高于5 mg和10 mg组;52周时HbA1c和体重均下降。

要点

  • 替尔泊肽5、10、15 mg组治疗中出现不良事件发生率分别为74%、74%、84%。
  • 最常见不良事件为轻度或中度鼻咽炎、恶心、便秘、腹泻和食欲下降。
  • 52周时HbA1c从基线8.5%~8.6%降至5.6%~6.0%,体重降低3.8~10.2 kg。

核心结论

  • 替尔泊肽作为日本2型糖尿病患者口服降糖单药治疗的附加治疗耐受性良好,并改善血糖控制和体重,与背景口服降糖药无关。
  • 替尔泊肽是单一口服降糖药控制不佳的日本2型糖尿病患者的潜在新治疗选择。

研究设计与样本

  • 多中心、开放标签、平行组、随机、3期试验,在日本34个医学研究中心和医院进行。
  • 纳入年龄≥20岁、HbA1c≥7.0%且<11.0%、接受口服降糖单药治疗至少3个月(筛选前稳定剂量≥8周)、BMI≥23 kg/m2、筛选前至少3个月体重稳定(±5%)的2型糖尿病患者。
  • 经过2周筛选和2周导入期后,参与者按1:1:1随机分配接受替尔泊肽5、10或15 mg每周一次皮下注射52周,随后4周安全性随访。
  • 所有参与者从2.5 mg开始,每4周增加2.5 mg直至达到分配剂量。
  • 主要终点为52周治疗期间的安全性及耐受性,以改良意向治疗(mITT)人群中治疗中出现不良事件的发生率评估。

主要发现

  • 2019年3月30日至2021年2月16日期间(招募和入组持续至2020年2月4日),484例参与者接受资格评估,443例随机分配并接受至少一剂替尔泊肽(5 mg组148例[33%],10 mg组147例[33%],15 mg组148例[33%])。
  • 398例(90%)参与者完成研究和治疗。
  • 443例中343例(77%)发生至少一次治疗中出现的不良事件;15 mg组125/148例(84%)高于5 mg组109/148例(74%)和10 mg组109/147例(74%)。
  • 最常见的治疗中出现不良事件为轻度或中度鼻咽炎75例(17%)、恶心74例(17%)、便秘54例(12%)、腹泻51例(12%)和食欲下降44例(10%)。
  • 第52周时,体重相对基线的平均变化为:5 mg组-3.8 kg(SE 0.5;降低5.1%),10 mg组-7.5 kg(SE 0.5;降低10.1%),15 mg组-10.2 kg(SE 0.5;降低13.2%)。

临床怎么用

  • 作者认为,替尔泊肽是单一口服降糖药控制不佳的日本2型糖尿病患者的潜在新治疗选择。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Due to potential ethnic differences in the pathophysiology of type 2 diabetes, new therapeutics need to be evaluated in Japanese patients. We aimed to assess the safety and glycaemic efficacy of tirzepatide as an add-on treatment in Japanese patients with type 2 diabetes who had inadequate glycaemic control with stable doses of various oral antihyperglycaemic monotherapies. METHODS: This multicentre, open-label, parallel-group, randomised, phase 3 trial was conducted at 34 medical research centres and hospitals in Japan. Eligible participants were aged 20 years or older with inadequately controlled (HbA1c ≥7·0% to <11·0%) type 2 diabetes and were receiving oral antihyperglycaemic monotherapy (sulfonylureas, biguanides, α-glucosidase inhibitors, thiazolidinedione, glinides, or SGLT2 inhibitors) for at least 3 months (stable dose for ≥8 weeks before screening), had a BMI of 23 kg/m2 or higher, and stable bodyweight (±5%) for at least 3 months before screening. After a 2-week screening and 2-week lead-in period, all participants were randomly assigned (1:1:1) to receive 5, 10, or 15 mg of tirzepatide, administered once per week subcutaneously for 52 weeks followed by a 4 week safety follow-up period, using a computer-generated random sequence and interactive web response system, stratified by oral antihyperglycaemic medication group. All participants started receiving 2·5 mg tirzepatide and doses were escalated by 2·5 mg every 4 weeks until the assigned dose was reached. The primary endpoint was safety and tolerability during 52 weeks of treatment, assessed as incidence of treatment-emergent adverse events in the modified intention-to-treat (mITT) population. This trial is registered with ClinicalTrials.gov, NCT03861039. FINDINGS: Between March 30, 2019, and Feb 16, 2021, with recruitment and enrolment continuing until Feb 4, 2020, 484 participants were assessed for eligibility and 443 were randomly assigned to receive at least one dose of tirzepatide (148 [33%] in the 5 mg group, 147 [33%] in the 10 mg group, and 148 [33%] in the 15 mg group). 398 (90%) participants completed the study and treatment. Most participants (343 [77%] of 443) had at least one treatment-emergent adverse event. Treatment-emergent adverse events were more frequent in the tirzepatide 15 mg group (125 [84%] of 148) than the 5 mg (109 [74%] of 148) and 10 mg groups (109 [74%] of 147). The most frequent treatment-emergent adverse events with tirzepatide were mild or moderate nasopharyngitis (75 [17%]), nausea (74 [17%]), constipation (54 [12%]), diarrhoea (51 [12%]), and decreased appetite (44 [10%]). At week 52, mean changes from baseline in bodyweight were -3·8 kg (SE 0·5; -5·1% reduction) in the 5 mg group, -7·5 kg (0·5; -10·1% reduction) in the 10 mg group, and -10·2 kg (0·5; -13·2% reduction) in the 15 mg group. Least squares mean HbA1c at baseline reduced from 8·5% (SE 0·1) to 6·0% (0·1) in the 5 mg tirzepatide group, from 8·6% (0·1) to 5·6% (0·1) in the 10 mg group, and from 8·6% (0·1) to 5·6% (0·1) in the 15 mg group at week 52. No adjudication-confirmed deaths were reported. INTERPRETATION: Tirzepatide was well tolerated as an add-on to oral antihyperglycaemic monotherapy in Japanese participants with type 2 diabetes and showed improvement in glycaemic control and bodyweight, irrespective of background oral antihyperglycaemic medication. Tirzepatide is a potential new treatment option for Japanese patients with type 2 diabetes that is inadequately controlled with single oral antihyperglycaemic medication. FUNDING: Eli Lilly and Company. TRANSLATION: For the Japanese translation of the abstract see Supplementary Materials section.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Kadowaki T, Chin R, Ozeki A, et al. Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial. Lancet Diabetes Endocrinol. 2022. PMID: 35914542. doi:10.1016/S2213-8587(22)00187-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。